NCT05332483View on ClinicalTrials.gov

Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

October 12, 2023

Study Completion Date

October 12, 2023

Conditions
Endometrial Cancer
Interventions
DRUG

Megestrol Acetate

Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences, Toronto

Sponsors
All Listed Sponsors
collaborator

Ontario Institute for Cancer Research

OTHER

lead

Sunnybrook Health Sciences Centre

OTHER